The 84th Annual Scientific Meeting of the Japanese Circulation Society JCS Abstracts

Introduction

[Speaker] Khung Keong Yeo:1
1:National Heart Centre Singapore, Singapore

SGLT2-I and HF overview of evidence and HF overview of evidence

[Speaker] Stephen Nicholls:1
1:Monash Heart, Monash University, Australia

Dyslipidemia: how low to go?

[Speaker] Junya Ako:1
1:Department of Cardiovascular Medicine, Kitasato University Hospital, Sagamihara

Statin intolerance: myths and pitfalls

[Speaker] Jian Jun Li:1
1:State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for CVDs, Chinese Academy of Medical Sciences, Peking Union Medical College, China

Fatty liver and heart disease

[Speaker] Eugenio B. Reyes:2
1:TBA, 2:University of the Philippines, Philippine General Hospital, Philippines

Introduction

[Speaker] Ashok Seth:1
1:Fortis Escorts Heart Institute & Research Centre, India

PCI vs medical treatment: Overview before ISCHEMIA Trial

[Speaker] Kenichi Tsujita:1
1:Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto

ISCHEMIA Trial: Summary and implications

[Speaker] Anwar Santoso:1
1:National Cardiovascular Centre - Harapan Kita Hospital; Universitas Indonesia - Dept Cardiology - Vascular Medicine, Indonesia

DOAC use in ACS and stable CAD: update on data

[Speaker] Alan Y. Y. Fong:1
1:Sarawak Heart Centre, Malaysia

Short DAPT

[Speaker] Yoshihisa Nakagawa:1
1:Department of Internal Medicine, Division of Cardiovascular Medicine, Shiga University of Medical Science, Otsu

ATTR amyloidosis.Where are these patients?

[Speaker] Pablo Garcia-Pavia:1
1:Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Spain

Main Results from the CREDO-Kyoto Cohort-3 in the New Generation DES Era

[Speaker] Takeshi Kimura:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Commentary

[Speaker] Stephan Windecker:1
1:Bern University Hospital, Switzerland

Discussion

Opening Special Lecture: Comparative Study of PCI versus CABG: Past, Present, and Future

[Speaker] Patrick W. Serruys:1
1:National University of Ireland Galway, Ireland

Discussion

Introduction

[Speaker] Yuji Ikari:1
1:Department of Cardiovascular Medicine, Tokai University School of Medicine, Isehara

Shockwave, Rota and CSI: how to choose

[Speaker] Michael Lee:1
1:Queen Elizabeth Hospital, Hong Kong

Cutting Balloons, Angiosculpt, ScoreFlex, OPN and other special balloons

[Speaker] Wei-Hsian Yin:1
1:Heart Center, Cheng Hsin General Hospital, Taiwan

OCT and IVUS for PIC guidance: which to choose

[Speaker] Hiromasa Otake:1
1:Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe

FFR, IFR and QFR: primer and how to choose

[Speaker] Yasutsugu Shiono:1
1:Department of Cardiovascular Medicine Wakayama Medical University, Wakayama

Introduction

[Speaker] Takanori Ikeda:1
1:Department of Cardiovascular Medicine, Toho University Faculty of Medicine, Tokyo

AF Ablation; indication & results of different technique

[Speaker] Teiichi Yamane:1
1:Department of Cardiology, the Jikei University School of Medicine, Tokyo

AF ablation in CHF: Who, When and How?

[Speaker] Yoshihide Takahashi:1
1:Department of Advanced Arrhythmia Research, Tokyo Medical and Dental University, Tokyo

Leadless and subcutaneous devices: updates and patients selection

[Speaker] Chih-Chieh Yu:1
1:Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taiwan

PV stenosis: a new problem?

[Speaker] Hong-Euy Lim:1
1:Hallym University, Korea

Section 1 PCI is the Preferred Management in Patients with LMCA Disease

Section 1. Backgrounds

[Speaker] Masanobu Ohya:1
1:Department of Cardiology, Kurashiki Central Hospital, Kurashiki

Section 1. Audience Response

Section 1. Pros: Yes, Look at PRECOMBAT, SYNTAX, and EXCEL.

[Speaker] Myeong-Ki Hong:1
1:Severance Cardiovascular Hospital, Yonsei University College of Medicine, Korea

Section 1. Cons: No, CABG is still the Gold Standard

[Speaker] Tohru Asai:1
1:Juntendo University, Tokyo

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Hirotoshi Watanabe:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 2 CABG is the Preferred Management in Patients with Extensive Multi-vessel CAD

Section 2. Backgrounds

[Speaker] Yukiko Nakano:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 2. Audience Response

Section 2. Pros: Yes, Look at the Randomized Trials

[Speaker] Shuichiro Takanashi:1
1:Cardiovascular Surgery, Kawasaki Saiwai Hospital, Kawasaki

Section 2. Cons: No, Look at SYNTAX-2

[Speaker] Patrick W. Serruys:1
1:National University of Ireland Galway, Ireland

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Upendra Kaul:1
1:Batra Heart Centre, India

Section 3 Ad-hoc PCI is the Preferred Strategy in Most Patients Undergoing Diagnostic Angiography

Section 3. Backgrounds

[Speaker] Toshiaki Toyota:1
1:Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe

Section 3. Audience Response

Section 3. Pros: Yes, Patients Do not Want Multiple Invasive Procedures

[Speaker] Adnan Kastrati:1
1:Deutsches Herzzentrum Munchen, Germany

Section 3. Cons: No, Informed Consent and Heart Team Approach are Crucial after Diagnostic Angiography

[Speaker] Hirokuni Arai:1
1:Department of Cardiovascular Surgery, Tokyo Medical and Dental University, Tokyo

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Hirotoshi Watanabe:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

State-of-the-Art
Current Treatment Strategies for Acute Aortic Dissection

[Speaker] Florian Schoenhoff:1
1:University Hospital Bern, Switzerland

Reconstruction of the Initial Evaluation and Care System of Acute Aortic Dissection

[Speaker] Hiroshi Imamura:1
[Co-author] Yuichiro Kashima:1, Koichiro Kuwahara:2
1:Department of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Matsumoto, 2:Department of Cardiology, Shinshu University School of Medicine, Matsumoto

Acute Aortic Syndrome Prior to Rupture and at Earlier Stage: Insights from Non-obstructive-general Angioscopy

[Speaker] Satoru Takahashi:1
[Co-author] Sei Komatsu:1, Yoshiharu Higuchi:2, Yasunori Ueda:3, Mitsuhiko Takewa:1, Masanori Asakura:4, Tomoki Ohhara:1, Atsushi Hirayama:2, Chikao Yutani:1, Kazuhisa Kodama:1
1:Cardiovascular Center, Osaka Gyomeikan Hospital, Osaka, 2:Department of Cardiology, Osaka Pollice Hospital, Osaka, 3:Department of Cardiology, National Hospital Organization Osaka National Hospital, Osaka, 4:Department of Cardiology, The Hospital of Hyogo College of Medicine, Nishinomiya

Aortic Angioscopy Assisted Thoracic Endovascular Repair for Chronic Type B Aortic Dissection -New Strategy for Aortic Team-

[Speaker] Hiroyuki Nishi:1
[Co-author] Yoshiharu Higuchi:2, Toshiki Takahashi:3, Shinya Fukui:1, Mutunori Kitahara:1, Kazuma Handa:1, Yumi Kakizawa:1, Yuma Hamanaka:2, Sei Komatsu:4, Atsushi Hirayama:2, Kazuhisa Kodama:4
1:Department of Cardiovascular Surgery, Osaka General Medical Center, Osaka, 2:Department of Cardiology, Osaka Police Hospital, Osaka, 3:Department of Cardiovascular Surgery, Osaka Police Hospital, Osaka, 4:Cardiovascular Center, Osaka Gyoumeikan Hospital, Osaka

Interarm Difference in Blood Pressure is Simple and Useful Diagnostic Marker of Type A Acute Aortic Dissection

[Speaker] Koichi Akutsu:1
[Co-author] Nozomi Sasamoto:1, Takeshi Yamamoto:2, Wataru Shimizu:1
1:Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, 2:Division of Intensive Cardiovascular Care, Nippon Medical School Hospital, Tokyo

State-of-the-Art
Evolution in Management Trends of Complex Aortic Disease with Focus on Aortic Dissection

[Speaker] Toru Suzuki:1
1:The University of Leicester, UK

Elucidation of The Pathological and Molecular Mechanism Underlying Arrhythmogenic Cardiomyopathy Caused by Tmem43 S358L Mutation

[Speaker] Haruki Shinomiya:1
[Co-author] Yoshihiro Asano:1, Hisakazu Kato:2, Yuki Kuramoto:1, Nozomi Watanabe:3, Toshihiro Tsuruda:4, Yohei Miyashita:5, Hidetaka Kioka:1, Seiji Takashima:2, Yasushi Sakata:1
1:Department of Cardiovascular Medicine, Osaka University, Suita, 2:Department of Medical Biochemistry, Osaka University Graduate School of Medicine, Suita, 3:Department of Cardiology, Miyazaki Medical Association Hospital Cardiovascular Center, Miyazaki, 4:Department of Internal Medicine, Circulatory and Body Fluid Regulation, Faculty of Medicine, University of Miyazaki, Miyazaki, 5:Department of Legal Medicine, Osaka University Graduate School of Medicine, Suita

Omega-3 Fatty Acid Epoxides Produced by PAF-AH2 from Mast Cells Regulate Pulmonary Vascular Remodeling

[Speaker] Hidenori Moriyama:1
[Co-author] Jin Endo:1, Masaharu Kataoka:1, Shinichi Goto:1, Akeo Hirai:1, Hidehiko Ikura:1, Seien Ko:1, Genki Ichihara:1, Takahiro Hiraide:1, Hiroki Kitakata:1, Kohsuke Shirakawa:1, Atsushi Anzai:1, Yoshinori Katsumata:1, Motoaki Sano:1, Keiichi Fukuda:1
1:Department of Cardiology, Keio University School of Medicine, Tokyo

Matrix Mechanotransduction Mediated by Thrombospondin-1/Integrin/Yap Signaling Pathway in The Remodeling of Blood Vessels

[Speaker] Yoshito Yamashiro:1
[Co-author] Bui Quoc Thang:2, Karina Ramirez:1, Seung Jae Shin:1, Tomohiro Kohata:3, Shigeaki Ohata:4, Tram Anh Vu Nguyen:1, Sumio Ohtsuki:3, Kazuaki Nagayama:4, Hiromi Yanagisawa:1
1:Life Science Center for Survival Dynamics, University of Tsukuba, Tsukuba, 2:Department of Cardiovascular Surgery, University of Tsukuba, Tsukuba, 3:Faculty of Life Sciences, Kumamoto University, Kumamoto, 4:Graduate School of Mechanical Systems Engineering, Ibaraki University, Ibaraki

Brown Adipose Tissue Dysfunction Promotes Metabolic Disorder in A Failing Heart

[Speaker] Yohko Yoshida:1
[Co-author] Ippei Shimizu:1, Tohru Minamino:1
1:Department of Cardiovascular Biology and Medicine/Division of Molecular Aging and Cell Biology, Niigata University Graduate School of Medical and Dental Sciences, Niigata

Common Problems and Differences between Western and Asian Patients with Atrial Fibrillation

[Speaker] Gregory Y. H. Lip:1
1:Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool Heart & Chest Hospital, UK

Current Perspectives on the Problems of Oral Anticoagulants Use for Atrial Fibrillation

[Speaker] Yasuo Okumura:1
1:Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo

Stroke Prevention in Atrial Fibrillation Patients with Difficult Scenarios: Aging and History of Intra-Cranial Hemorrhage

[Speaker] Tze-Fan Chao:1
1:Taipei Veterans General Hospital, Taiwan

Prognosis and Causes of Death in Patients with Atrial Fibrillation

[Speaker] Yoshimori An:1
1:National Hospital Organization Kyoto Medical Center, Department of Cardiology, Kyoto

Role of Catheter Ablation for Atrial Fibrillation in the Prevention of Cardiovascular Events

[Speaker] Koonlawee Nademanee:1
1:Pacific Rim Electrophysiology Research Institute, Los Angeles, USA

How to Manage Asian Patients with Atrial Fibrillation

[Speaker] Chu-Pak Lau:1
1:Queen Mary Hospital, The University of Hong Kong, Hong Kong

Section 1 P2Y12 Receptor Blocker Monotherapy is the Standard Long-term Antiplatelet Therapy after Coronary Stenting

Section 1. Backgrounds

[Speaker] Kyohei Yamaji:1
1:Division of Cardiology, Kokura Memorial Hospital, Kitakyushu

Section 1. Audience Response

Section 1. Pros: Yes, Aspirin Free Strategy is the Way to Go

[Speaker] Patrick W. Serruys:1
1:National University of Ireland Galway, Ireland

Section 1. Cons: No, Aspirin is still the GLOBAL LEADER

[Speaker] Deepak Bhatt:1
1:Brigham and Women's Hospital, Harvard Medical School, USA

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Kyohei Yamaji:1
1:Division of Cardiology, Kokura Memorial Hospital, Kitakyushu

Section 2 Very Short DAPT after PCI is the Choice Even in High Ischemic Risk Patients

Section 2. Backgrounds

[Speaker] Yoshinobu Onuma:1
1:National University of Ireland Galway, Ireland

Section 2. Audience Response

Section 2. Pros: Yes, Look at the STOPDAPT-2, SMART-CHOICE and TWILIGHT.

[Speaker] Adnan Kastrati:1
1:Deutsches Herzzentrum Munich, Germany

Section 2. Pros: Yes, I would Agree with the Benefit of Short DAPT after PCI, but How We could Reconcile the Benefit of Short DAPT with the Evidence Favoring More Intensive Antithrombotic Therapy in DAPT, PEGASUS, and COMPASS Trials

[Speaker] Marc S. Sabatine:1
1:TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Yoshinobu Onuma:1
1:National University of Ireland Galway, Ireland

Section 3 How Far should We Pursue More Intensive Lipid-lowering in High-risk CAD Patients?

Section 3. Backgrounds

[Speaker] Katsumi Miyauchi:1
1:Juntendo Tokyo Geriatric Medical Center, Tokyo

Section 3. Audience Response

Section 3. Pros: Ezetimibe, PCSK-9 Inhibitors, and EPA are Proven Effective

[Speaker] Stephen J. Nicholls:1
1:Monash Heart, Monash University, Australia

Section 3. Cons: High-intensity Statins Therapy is Sufficient in Most Japanese CAD Patients

[Speaker] Toshiaki Toyota:1
1:Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Katsumi Miyauchi:1
1:Juntendo Tokyo Geriatric Medical Center, Tokyo

Introduction

[Speaker] Issei Komuro:1
1:Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo

New therapies for HFREF: overview, effect size and priority

[Speaker] Masaru Hatano:1
1:The University of Tokyo, Tokyo

HFPEF: are we any nearer?

[Speaker] Chung-Lieh Hung:1
1:Division of Cardiology, Department. of Internal Medicine, MacKay Memorial Hospital, Taiwan

MitraClip for MR: overview in Asia

[Speaker] Khung Keong Yeo:1
1:National Heart Centre Singapore, Singapore

TAVI: ready for low risk patients?

[Speaker] Kentaro Hayashida:1
1:Department of Cardiology, Keio University School of Medicine, Tokyo

Introduction

[Speaker] Takashi Kubo:1
1:Wakayama Medical University, Wakayama

Advances in PET-CT Fusion imaging

[Speaker] Nobuhiro Tahara:1
1:Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume

New techniques of echocardiography

[Speaker] Jae Kwan Song:1
1:Asan Medical Center, University of Ulsan College of Medicine, Korea

Advances in CTCA

[Speaker] Makoto Orii:1
1:Department of Radiology Iwate Medical University, Morioka

Advances in CMR

[Speaker] Calvin Chin Woon Loong:1
1:National Heart Centre Singapore, Singapore

Keynote Lecture
How to Diagnose Pulmonary Hypertension and Right Heart Failure

[Speaker] Kaoru Dohi:1
1:Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu

Right Ventricular Response to Severe Functional Tricuspid Regurgitation: A 3D TEE-Based Functional and Morphological Analysis

[Speaker] Hiroto Utsunomiya:1
[Co-author] Yu Harada:1, Hitoshi Susawa:1, Hiroki Ikenaga:1, Yukihiro Fukuda:1, Yasuki Kihara:1
1:Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima

Right Ventricular Three-dimensional Dyssynchrony Analysis for Cardiac Resynchronization

[Speaker] Tomoko Ishizu:1
[Co-author] Masaki Ieda:1
1:Department of Clinical Laboratory Medicine, Univeristy of Tsukuba, Tsukuba, 2:Department of Cardiovascular Medicine, University of Tsukuba, Tsukuba

Right Ventricular Failure and the Diameters of Pulmonary Artery and Ascending Aorta; As a Marker of Disease Chronicity

[Speaker] Tomohito Ohtani:1
[Co-author] Misato Chimura:1, Yasushi Sakata:1
1:Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita

TLR9-NF-κB‒Mediated Sterile Inflammation is a Novel Therapeutic Target for Right Ventricular Dysfunction

[Speaker] Keimei Yoshida:1
[Co-author] Kotaro Abe:1, Keita Saku:1, Tomohito Ishikawa:1, Takanori Watanabe:1, Kazuya Hosokawa:1, Hiroyuki Tsutsui:1
1:Departments of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, 2:Aso Iizuka Hospital, Iizuka

Discussion

Validation and Optimization of the JCS 2018 Guideline for the Recommendations of ICD Therapy in Patients with Hypertrophic Cardiomyopathy

[Speaker] Yasuki Hen:1
[Co-author] Nobuo Iguchi:2, Mitsuru Kanisawa:3, Kaori Takada:3, Haruhiko Machida:4, Ayako Takara:1, Kunihiko Teraoka:1, Itaru Takamisawa:2, Morimasa Takayama:2, Tsutomu Yoshikawa:1
1:Department of Cardiology, Sakakibara Heart Clinic, Tokyo, 2:Department of Cardiology, Sakakibara Heart Institute, Tokyo, 3:Department of Radiology, Sakakibara Heart Institute, Tokyo, 4:Kyorin University School of Medicine, Mitaka

Primary and Secondary Prevention of Adverse Cardiac Events with Implantable Cardioverter Defibrillator -Lessons from Real-world Data-

[Speaker] Takashi Shiroto:1
[Co-author] Yasuhiko Sakata:1, Kotaro Nochioka:1, Makoto Nakano:1, Koichiro Sugimura:1, Jun Takahashi:1, Satoshi Miyata:2, Hiroaki Shimokawa:1
1:Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, 2:Department of Evidence-based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai

Improvement of Left Ventricular Ejection Fraction and Sudden Cardiac Death in Japanese Patients with Heart Failure

[Speaker] Atsushi Suzuki:1
[Co-author] Tsuyoshi Shiga:2, Shintaro Haruki:1, Noriko Kikuchi:1, Erisa Watanabe:1, Hidetoshi Hattori:1, Yuichiro Minami:1, Tsuyoshi Suzuki:1, Morio Shoda:1, Nobuhisa Hagiwara:1
1:Department of Cardiology, Tokyo Women's Medical University, Tokyo, 2:Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo

Electrical Storm and Role of an Implantable Cardioverter Defibrillator in the Elder in Japan

[Speaker] Takashi Noda:1
[Co-author] Nobuhiko Ueda:1, Kohei Ishibashi:1, Kengo Kusano:1, Satoshi Yasuda:1, Takashi Nitta:2, Yoshihusa Aizawa:3, Toru Ohe:4, Takashi Kurita:5
1:Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, 2:Department of Cardiovascular Surgery, Nippon Medical School, Tokyo, 3:Department of Research and Development, Tachikawa Medical Center, Nagaoka, 4:Department of Cardiology, Okayama City Hospital, Okayama, 5:Department of Internal Medicine, Faculty of Medicine, Kindai University, Sayama

Management of Modifiable Risk Factors for the Development of Afib

[Speaker] Gregory Y. H. Lip:1
1:Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool Heart & Chest Hospital, UK

Up-stream Approach for Prevention of Afib with Suppression of Renin-angiotensin System: Differences in Animal Models and Clinical Studies

[Speaker] Yoshio Takemoto:1
1:Gifu Prefectural Tajimi Hospital, Tajimi

Pulmonary Vein Isolation as a Primary Prevention of Afib in Patients Undergoing Ablation for Atrial Flutter

[Speaker] Naoaki Onishi:1
1:Otsu Red Cross Hospital, Department of Cardiology, Otsu

Artificial Intelligence can Identify Patients with Paroxysmal Afib by Evaluating 12 Leads ECGs with Sinus Rhythm

[Speaker] Tetsuo Sasano:1
1:Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo

Implantable Cardiac Monitoring System for Afib Detection

[Speaker] Ritsuko Kohno:1
1:Department of Heart Rhythm Management, University of Occupational and Environmental Health, Japan, Kitakyushu

Novel Afib Detection Modalities

[Speaker] Yuki Iwasaki:1
1:Department of Cardiovascular Medicine, Nippon Medical School, Tokyo

Prognosis and Genetic Background of Mitochondrial Cardiomyopathy in 223 Mitochondrial Disease Patients

[Speaker] Atsuko Okazaki:1
[Co-author] Yoshihito Kishita:1, Masakazu Kohda:1, Takuya Fushimi:2, Ayako Matsunaga:2, Yosuke Mizuno:3, Yukiko Yatsuka:1, Tomoko Hirata:4, Hiroko Harashima:5, Atsuhito Takeda:6, Akihiro Nakaya:7, Shigetoyo Kogaki:8, Yasushi Sakata:9, Akira Ohtake:5, Kei Murayama:2, Yasushi Okazaki:1
1:Medical Genomics Center/Diagnostics and Therapeutics of Intractable Diseases, National Center for Global Health and Medicine/Juntendo University, Tokyo, 2:Department of Metabolism, Chiba Children's Hospital, Chiba, 3:Division of Functional Genomics & Systems Medicine, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, 4:Laboratory for Comprehensive Genomic Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, 5:Department of Pediatrics, Saitama Medical University, Iruma, 6:Department of Pediatrics, Graduate School of Medicine, Hokkaido University, Sapporo, 7:Department of Genome Informatics, Osaka University Graduate School of Medicine, Suita, 8:Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, 9:Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita

Novel Concept of Rnf213-Associated Vascular Diseases: Prognostic Impact in Pulmonary Arterial Hypertension

[Speaker] Takahiro Hiraide:1
[Co-author] Masaharu Kataoka:1, Yoshinori Katsumata:1, Shinichi Goto:1, Hidenori Moriyama:1, Hiroki Kitakata:1, Kosuke Shirakawa:1, Atsushi Anzai:1, Jin Endo:1, Motoaki Sano:1, Yoji Hakamata:3, Kenjiro Kosaki:2, Keiichi Fukuda:1
1:Department of Cardiology, Keio University School of Medicine, Tokyo, 2:Center for Medical Genetics, Keio University School of Medicine, Tokyo, 3:Department of Basic Science, School of Veterinary Nursing and Technology, Faculty of Veterinary Science, Nippon Veterinary and Life Science University, Tokyo

Quality Indicators and Outcomes of Acute Aortic Dissection: Analyses of The Nationwide Jroad-Dpc Data

[Speaker] Tetsuo Yamaguchi:1
[Co-author] Michikazu Nakai:2, Yoko Sumita:2, Yoshihiro Miyamoto:2, Hitoshi Matsuda:3, Yousuke Inoue:3, Hideaki Yoshino:4, Yutaka Okita:5, Kenji Minatoya:6, Yuichi Ueda:7, Hitoshi Ogino:8
1:Department of Cardiovascular Center, Toranomon Hospital, Tokyo, 2:Center for Cerebral and Cardiovascular Disease Information, National Cerebral and Cardiovascular Center, Suita, 3:Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, 4:Department of Cardiology, Kyorin University Graduate School of Medicine, Tokyo, 5:Department of Cardiovascular Surgery, Kobe University Graduate School of Medicine, Kobe, 6:Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, 7:Department of Cardiology, Nara Prefecture General Medical Center, Nara, 8:Department of Cardiovascular Surgery, Tokyo Medical University, Tokyo

Bacteroides Decrease Human Faecal Lipopolysaccharide Levels

[Speaker] Naofumi Yoshida:1
[Co-author] Tomoya Yamashita:1, Tokiko Tabata:1, Yoshihiro Saito:1, Takuo Emoto:1, Tomohiro Hayashi:1, Masakazu Shinohara:2, Ken-Ichi Hirata:1
1:Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, 2:Division of Epidemiology, Kobe University Graduate School of Medicine, Kobe

Section 1 Leadless Pacemaker is Preferred over Conventional Transvenous Pacemaker for Patients with Bradyarrhythmia and Sinus Rhythm at High-risk for Device Infection

Section 1. Backgrounds

[Speaker] Kenji Ando:1
1:Cardiology Department, Kokura Memorial Hospital, Kitakyushu

Section 1. Audience Response

Section 1. Pros: Leadless Pacemaker is Safe and Feasible with Very Short Procedure Time and Low Complication Rates

[Speaker] Moritoshi Funasako:1
1:Na Homolce Hospital, Czech

Section 1. Cons: Incidence of Pacemaker Syndrome after VVI Pacemaker Implantation in Patients with Bradycardia and Sinus Rhythm is Substantially High

[Speaker] Toshiyuki Ishikawa:1
1:Department of Cardiology, Yokohama City University Hospital, Yokohama

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Kenji Ando:1
1:Cardiology Department, Kokura Memorial Hospital, Kitakyushu

Section 2 Conventional RV Pacemaker in Patients with AV Conduction Disturbance and Low LVEF should be Upgraded to Biventricular Pacemaker at the Time of Battery Exchange Even when Heart Failure Symptom is Mild

Section 2. Backgrounds

[Speaker] Anne B. Curtis:1
1:University at Buffalo School of Medicine and Biomedical Sciences, USA

Section 2. Audience Response

Section 2. Pros: RV Pacemaker should be Mostly Upgraded to Physiological Pacing in Patients with Reduced LV Function

[Speaker] Kenji Ando:1
1:Cardiology Department, Kokura Memorial Hospital, Kitakyushu

Section 2. Cons: Most of Patients with Permanent Pacemaker and AV Conduction Disturbance are Elderlies with High Risk of Device Infection and the Battery Exchange Procedure should be Simple

[Speaker] Morio Shoda:1
1:Tokyo Women's Medical University, Department of Cardiology, Tokyo

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Anne B. Curtis:1
1:University at Buffalo School of Medicine and Biomedical Sciences, USA

Section 3 CRT should be Considered Even when QRS is Relatively Narrow in Patients with CLBBB, Sinus Rhythm, Heart Failure, and Low LVEF

Section 3. Backgrounds

[Speaker] Takashi Kurita:1
1:Division of Cardiovascular Center, Kindai University, Osakasayama

Section 3. Audience Response

Section 3. Pros: CRT should be Liberally Performed Even for Patients with Relatively Narrow QRS of 120-130ms Especially in Countries with Few Cardiac Transplantations Like Japan

Section 3. Cons: Evidence of the Efficacy of CRT for Patients with QRS of 120-130ms is Inadequate

[Speaker] Takashi Noda:1
1:National Cerebral and Cardiovascular Center, Suita

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Takashi Kurita:1
1:Division of Cardiovascular Center, Kindai University, Osakasayama

Section 1 Very Short DAPT is the Way to Go after DES Implantation

Section 1. Openig Lecture

[Speaker] Hirotoshi Watanabe:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 1. Audience Response

Section 1. Position Statement

[Speaker] Takeshi Kimura:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 1. Panel Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Adnan Kastrati:1
1:Deutsches Herzzentrum Munchen, Germany

Section 2 Triple Antithrombotic Therapy is Contraindicated in AF Patients Undergoing PCI

Section 2. Openig Lecture

[Speaker] Junya Ako:1
1:Kitasato University, Tokyo

Section 2. Audience Response

Section 2. Positon Statement

[Speaker] Deepak Bhatt:1
1:Brigham and Women's Hospital, Harvard Medical School, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Yoshihiro Morino:1
1:Department of Cardiology, Iwate Medical University, Morioka

Section 3 OAC Alone is Enough in AF Patients beyond 1-year after PCI

Section 3. Openig Lecture

[Speaker] Yukiko Nakano:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 3. Audience Response

Section 3. Position Statement

[Speaker] Satoshi Yasuda:1
1:National Cerebral and Cardiovascular Center, Suita

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Adnan Kastrati:1
1:Deutsches Herzzentrum Munchen, Germany

Introduction & Overview of HT in Asia

[Speaker] Naoyuki Hasebe:1
1:Department of Internal Medicine, Cardiology, Nephrology, Pulmonology and Neurology Division, Asahikawa Medical University, Asahikawa

Current & future HT guideline in China

[Speaker] Jiguang Wang:1
1:Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

Big data of HT practice in Korea

[Speaker] Sungha Park:1
1:Yonsei University College of Medicine, Korea

Current & future HT guideline in Taiwan

[Speaker] Tzung-Dau Wang:1
1:National Taiwan University Hospital, Taiwan

Big data of HT practice in Japan

[Speaker] Mitsuru Ohishi:1
1:Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima

Introduction

[Speaker] Teiji Akagi:1
1:Department of Cardiovascular Medicine, Okayama University, Okayama

Reoperation in Tetralogy of Fallot (TOF)

[Speaker] Jimei Chen:1
1:Guangdong provincial people's hospital, Guangzhou, China

Management of arrhythmias in Fontan

[Speaker] Aya Miyazaki:1
1:Department of Transition Medicine, Division of Congenital Heart Disease, Shizuoka General Hospital, Shizuoka

Pulmonary artery hypertention in Asia

[Speaker] Lucia Krisdinarti:1
1:Gadjah Mada University, Indonesia

Management of high-pregnancy

[Speaker] Lucy Youngmin Eun:1
1:Yonsei University College of Medicine, Severance Hospital, Seoul, Korea

Baseline Clinical Characteristics in a Large-scale Registration Survey of Patient with Hypertrophic Cardiomyopathy throughout Japan: J-HCM Registry Study

[Speaker] Toru Kubo:1
1:Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Nankoku

Commentary

[Speaker] Morimasa Takayama:1
1:Department of Cardiology, Sakakibara Heart Institute, Fuchu

Discussion

One-year Outcomes of the Pivotal Clinical Trial of a Balloon-expandable Transcatheter Aortic Valve Implantation in Japanese Dialysis Patients

[Speaker] Koichi Maeda:1
1:Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita

Commentary

[Speaker] Yuichi Kawase:1
1:Department of Cardiology, Kurashiki Central Hospital, Kurashiki

Discussion

The Nationwide Registry of Hospitalized Heart Failure Patients in Japan: Japanese Registry of Acute Decompensated Heart Failure (JROADHF) and JROADHF-NEXT

[Speaker] Tomomi Ide:1
1:Department of Cardiovascular Medicine, Kyushu University, Fukuoka

Commentary

[Speaker] Fusako Sera:1
1:Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita

Discussion

Efficacy and Safety Analysis of Initial Impella Experience in Japan. A Novel Percutaneous Hemodynamic Support Device: Report from J-PVAD Registry

[Speaker] Yoshiki Sawa:1
1:Department of Cardiovascular Surgery, Osaka University, Suita

Commentary

[Speaker] Shin Watanabe:1
1:Kyoto University, Kyoto

Discussion

Sympathetic Innervation Facilitated The Self-Organization of Ips Cell-Derived Cardiac Tissues

[Speaker] Li Jun:1
[Co-author] Jong-Kook Lee:2, Yuki Kuramoto:1, Yasushi Sakata:1
1:Department of Cardiovascular Medicine, Osaka University, Suita, 2:Department of Advanced Cardiovascular Regenerative Medicine, Osaka University Graduate School of Medicine, Suita

Stimulator of Interferon Genes Plays A Crucial Role in Atherogenesis via Macrophages Activation in Apolipoprotein E-Deficient Mice

[Speaker] Pham Tran Phuong:1
[Co-author] Daiju Fukuda:2, Masataka Sata:1
1:Cardiovascular Medicine, Tokushima University, Tokushima, 2:Department of Cardio-Diabetes Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima

Role of The Left Anterior Descending Artery Flow Velocity in Regional Myocardial Washout Rate of Thallium-201 in Patients without Significant Perfusion Abnormality

[Speaker] Erasta Ramandika:1
[Co-author] Satoshi Kurisu:1, Kazuhiro Nitta:1, Takayuki Hidaka:1, Hiroto Utsunomiya:1, Ken Ishibashi:1, Hiroki Ikenaga:1, Yukihiro Fukuda:1, Yasuki Kihara:1
1:Cardiovascular Medicine, Hiroshima University, Hiroshima

Endothelial Cell-Derived Activin A is Critically Involved in Pulmonary Arterial Hypertension through Mediating Bmpr-Ii Degradation in Endothelial Cell

[Speaker] Gusty Rizky Teguh Ryanto:1
[Co-author] Koji Ikeda:2, Kazuya Miyagawa:2, Yoko Suzuki:2, Ken-Ichi Hirata:1, Noriaki Emoto:2
1:Cardiovascular Medicine, Kobe University, Kobe, 2:Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe

Remaining Issues around TAVI

[Speaker] Shigeru Saito:1
1:Shonan Kamakura General Hospital, Division of Cardiology & Catheterization Laboratories, Kamakura

Choice of Intervention TAVI or SAVR

[Speaker] Kotaro Obunai:1
1:Tokyo Bay Medical Center, Department of Cardiology, Tokyo

Device Selection: SAPIEN/CoreValve/Other Valves

[Speaker] Norio Tada:1
1:Cardiology Sendai Kosei Hospital, Sendai

Coronary Occlusion: How to Prevent and Manage?

[Speaker] Yasushi Fuku:1
1:Kurashiki Central Hospital, Kurashiki

HALT and Stroke: How to Prevent and Manage?

[Speaker] Nobuhiro Yoshijima:1
1:Keio University Hospital, Cardiology, Tokyo

Future Directions of TAVI

[Speaker] Stephan Windecker:1
1:Bern University Hospital, Switzerland

The 3rd generation laser balloon: Its potential advantages over conventional modalities

[Speaker] Moritoshi Funasako:1
1:Na Homolce Hospital, Czech Republic

Rhythmia: Ultra-high-resolution mapping for AT ablation and SVC isolation

[Speaker] Yasuaki Tanaka:1
1:Yokosuka Kyosai Hospital, Yokosuka

Novel NavX Technology: High resolution mapping with HD grid

[Speaker] Kenji Okubo:1
1:Yokosuka Kyosai Hospital Cardiovascular Center, Yokosuka

High power-short duration RFCA with QDOT Smart and QMODE Plus

[Speaker] Hiroshi Nakagawa:1
1:Cleveland Clinic, USA

Expandable lattice electrode ablation Catheter of Affera

[Speaker] Petr Neuzil:1
1:Na Homolce Hospital, Czech Republic

Pulsed field ablation: Will it be One of the future major energy source for PV isolation?

[Speaker] 舩迫 宴福:1
1:Na Homolce Hospital, Czech Republic

Keynote Lecture
CCTA/FFRCT to Guide Coronary Revascularization

[Speaker] Jonathon Leipsic:1
1:University of British Columbia, Canada

FFR-CT for Treatment Decision Making in Patients with Complex Coronary Artery Disease

[Speaker] Jeroen Bax:1
1:Leids Universitair Medisch Centrum, The Netherlands

Impact of FFR-CT Guided Care in Patients with Suspected Stable Coronary Artery Disease

[Speaker] Hiroyoshi Yokoi:1
1:Department of Cardiology, Fukuoka Sanno Hospital, Fukuoka

FFR-CT as a Practical Tool in Optimizing PCI Strategy

[Speaker] Toru Miyoshi:1
1:Department of Cardiovascular Medicine, Okayama University Hospital, Okayama

Will FFR-CT Replace Stress Perfusion Imaging in Guiding Coronary Interventions in Japan?

[Speaker] Hitoshi Matsuo:1
[Co-author] Yoshihiro Sobue:1, Masayasu Nakagawa:1, Hiroyuki Omori:1, Toru Tanigaki:1, Munenori Okubo:1, Hideaki Ota:1, Taiji Miyake:1, Jun Kikuchi:1, Tetsuo Hirata:1, Itta Kawamura:1, Hiroki Kamiya:1, Kunihiko Tsuchiya:1, Takuya Mizukami:2, Takeshi Kondo:1, Takahiko Suzuki:3
1:Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, 2:Cardiovascular Center, OLV Hospital, Belgium, 3:Department of Cardiovascular Medicine, Toyohashi Heart Center, Toyohashi

Discussion

Section 1 PFO should be Closed in Most Patients with Cryptogenic Stroke

Section 1. Backgrounds

[Speaker] Akio Kawamura:1
1:Cardiology, School of Medicine, International University of Health and Welfare, Tokyo

Section 1. Audience Response

Section 1. Pros: Yes, Look at the RESPECT and Other Clinical Data

[Speaker] John D. Carroll:1
1:Division of Cardiology, Department of Medicine, University of Colorado Denver, USA

Section 1. Cons: No, Oral Anticoagulation is Enough for Older Patients

[Speaker] Koichi Oki:1
1:Department of Neurology, Stroke Center, Tokyo Saiseikai Central Hospital, Tokyo

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Teiji Akagi:1
1:Department of Cardiovasucular Medicine, Okayama University, Okayama

Section 2 ASD should be Closed after Controlling Pulmonary Hypertension

Section 2. Backgrounds

[Speaker] Masao Imai:1
1:Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki

Section 2. Audience Response

Section 2. Pros: Yes, Pulmonary Hypertension should be Extensively Treated before ASD Occlusion

[Speaker] Yuichi Tamura:1
1:Department of Cardiology, International University of Health and Welfare School of Medicine/Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo

Section 2. Cons: No, ASD could be Closed before Treatment of Pulmonary Hypertension in Selected Patients

[Speaker] Yoichi Takaya:1
1:Department of Cardiovasucular Medicine, Okayama University, Okayama

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Shinobu Hosokawa:1
1:Department of Cardiology, Tokushima Red Cross Hospital, Komatsushima

Section 3 LAA Closure is Preferable to Oral Anticoagulation in Many AF Patients with High Bleeding Risk

Section 3. Backgrounds

[Speaker] Hidehiko Hara:1
1:Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo

Section 3. Audience Response

Section 3. Pros: Yes, LAA Closure is a Breakthrough Treatment for AF Patients

[Speaker] Yoshihiro Morino:1
1:Department of Cardiology, Iwate Medical University, Morioka

Section 3. Cons: No, Anticoagulation is the Gold Standard Therapy for Stroke Prevention

[Speaker] Masaharu Akao:1
1:Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Teiji Akagi:1
1:Department of Cardiovascular Medicine, Okayama University, Okayama

Section 1 Unload LV with Impella before Reperfusion in Patients with Large Anterior STEMI without Shock

Section 1. Backgrounds

[Speaker] Keita Saku:1
1:Kyushu University, Department of Cardiovascular Medicine, Fukuoka

Section 1. Audience Response

Section 1. Pros: Yes, Unloading First!

[Speaker] Navin K. Kapur:1
1:Tufts Medical Center, USA

Section 1. Cons: No, Reperfusion First!

[Speaker] Kazuoki Dai:1
1:Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

Section 2 Culprit-only Revascularization for Multivessel Disease is the Rule in STEMI Patients with Cardiogenic Shock

Section 2. Backgrounds

[Speaker] Tetsuya Tobaru:1
1:Kawasaki Saiwai Hospital, Department of Cardiology, Kawasaki

Section 2. Audience Response

Section 2. Pros: Yes, Look at CULPRIT-SHOCK Trial

[Speaker] Takenori Domei:1
1:Kokura Memorial Hospital, Kitakyushu

Section 2. Cons: No, CULPRIT-SHOCK Trial Excluded Those Patients Who could Benefit from Complete Revascularization

[Speaker] Hiroki Sakamoto:1
1:Shizuoka General Hospital, Shizuoka

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

Section 3 Under Feeding is Needed for Patients with Cardiovascular Disease in Intensive Care Unit

Section 3. Backgrounds

[Speaker] Hitoshi Sato:1
1:National Cerebral and Cardiovascular Center, Department of Critical Care Medicine, Suita

Section 3. Audience Response

Section 3. Pros: Yes, Overfeeding should be Avoided to Prevent Refeeding Syndrome

[Speaker] Naoki Higashibeppu:1
1:Department of Anesthesia and Critical Care, Kobe City Medical Center General Hospital Kobe City Hospital Organization, Kobe

Section 3. Cons: No, Full Feeding is Needed

[Speaker] Kentaro Shimizu:1
1:Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

Section 1. SGLT-2 Inhibitor, but not Metoformin, is the First-line Treatment for Diabetic Patients with High Cardiovascular Risk

Section 1. Opening Lecture

[Speaker] Eri Kato:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 1. Audience Response

Section 1. Position Statement

[Speaker] Darren K. Mcguire:1
1:University of Texas Southwestern Medical Center, USA

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusion

[Speaker] Koichi Node:1
1:Department of Cardiovascular Medicine, Saga University, Saga

Section 2. SGLT-2 Inhibitor is the Key Drug for Renal Protection in CKD Patients

Section 2. Opening Lecture

[Speaker] Ko Yamamoto:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 2. Audience Response

Section 2. Position Statement

[Speaker] Motoko Yanagita:1
1:Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusion

[Speaker] Koichiro Kuwahara:1
1:Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto

Section 3. SGLT-2 Inhibitor is the Heart Failure Medication in Patients without Diabetes

Section 3. Opening Lecture

[Speaker] Yodo Tamaki:1
1:Department of Cardiology, Tenri Hospital, Tenri

Section 3. Audience Response

Section 3. Position Statement

[Speaker] Felipe Alberto Martinez:1
1:Instituto DAMIC - Fundacion Rusculleda, Argentina

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusion

[Speaker] Marc S. Sabatine:1
1:TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, USA

Section 1 DOACs for NVAF should be Strictly Used with Approved Doses

Section 1. Backgrounds

[Speaker] Ken Okumura:1
1:Saiseikai Kumamoto Hospital, Kumamoto

Section 1. Audience Response

Section 1. Pros: Yes, DOAC Usage with Non-approved Dose is Associated with High Risk of Cardiovascular Events

[Speaker] Koichi Inoue:1
1:Sakurabashi Watanabe Hospital, Osaka

Section 1. Cons: No, Approved Doses of DOACs are Often Overdosages for Asians Especially in Aging Countries Like Japan

[Speaker] Masaharu Akao:1
1:Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Ken Okumura:1
1:Saiseikai Kumamoto Hospital, Kumamoto

Section 2 Catheter Ablation for AF is Reasonable Even in Asymptomatic Patients

Section 2. Backgrounds

[Speaker] Kazutaka Aonuma:1
1:Cardiology Department, Institute of Clinical Medicine, University of Tsukuba, Tsukuba

Section 2. Audience Response

Section 2. Pros: Yes. Patients Undergoing Catheter Ablation for AF is Associated with Very Low Risk of Stroke Regardless of AF Symptoms

[Speaker] Satoshi Shizuta:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 2. Cons: No. Risk and Benefit Ratio of Catheter Ablation for Asymptomatic AF is Unclear

[Speaker] Hiroshi Nakagawa:1
1:Cleveland Clinic, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Kazutaka Aonuma:1
1:Cardiology Department, Institute of Clinical Medicine, University of Tsukuba, Tsukuba

Section 3 Uninterrupted OAC is Preferred over Interrupted OAC with Heparin Bridging in AF Ablation

Section 3. Backgrounds

[Speaker] Satoshi Shizuta:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 3. Audience Response

Section 3. Pros: Yes. All AF Ablation should be Performed with Uninterrupted OAC

[Speaker] David Spragg:1
1:Johns Hopkins University School of Medicine, USA

Section 3. Cons: No. Minimally Interrupted OAC is Safe and Feasible in Most AF Ablation

[Speaker] Akihiko Nogami:1
1:Department of Cardiology, University of Tsukuba, Tsukuba

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Satoshi Shizuta:1
1:Taipei Veterans General Hospital, National Yang Ming University, Taiwan

Section 1 Should We Adhere to the Guideline-recommended Therapies in Super-elder HFrEF Patients?

Section 1. Backgrounds

[Speaker] Erika Yamamoto:1
1:Kyoto University Hospital, Kyoto

Section 1. Audience Response

Section 1. Pros: Yes, but How Long?

[Speaker] Hidenori Yaku:1
1:Mitsubishi Kyoto Hospital/Kyoto University, Kyoto

Section 1. Cons: No, Physical Functional Status is the Determinant

[Speaker] Takayuki Inomata:1
1:Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital, Tokyo

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Yukihito Sato:1
1:Division of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki

Section 2 Do We Really Need the HFmrEF Category?

Section 2. Backgrounds

[Speaker] Tetsuari Onishi:1
1:Himeji Cardiovascular Center, Department of Cardiology, Himeji

Section 2. Audience Response

Section 2. Pros: Yes, HFmrEF is Distinct Entity

[Speaker] Miyuki Ito:1
1:Cardiovascular Imaging Clinic Iidabashi, Tokyo

Section 2. Cons: No, HFmrEF is not Clinically Relevant

[Speaker] Wai Hong Wilson Tang:1
1:Heart and Vascular Institute, Cleveland Clinic, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Hiroyuki Tsutsui:1
1:Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka

Section 3 Is Exercise Rehabilitation Indicated in Patients with Advanced Heart Failure Receiving an Intravenous Inotropic Agents?

Section 3. Background

[Speaker] Hitoshi Adachi:1
1:Gunma Prefectural Cardiovascular Disease, Maehashi

Section 3. Audience Response

Section 3. Pros: Yes, When and How?

[Speaker] Taiki Higo:1
1:Kyushu University Hospital, Cardiovascular Medicine, Fukuoka

Section 3. Cons: Case by Case

[Speaker] Takuya Watanabe:1
1:National Cerebral and Cardiovascular Center, Suita

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Yoichi Goto:1
1:Yoka Municipal Hospital, Yabu

Introduction

[Speaker] Yoshihiko Saito:1
1:Department of Cardiovascular Medicine, Nara Medical University, Nara

Skeletal muscle dysfunction

[Speaker] Shintaro Kinugawa:1
1:Faculty of Medical Sciences, Department of Experimental and Clinical Cardiovascular Medicine, Kyushu University, Fukuoka

Coronary artery disease

[Speaker] Sodiqur Rifqi:1
1:Dr. Kariadi General Hospital / Medical Faculty of Diponegoro University, Indonesia

Diabetes Mellitus

[Speaker] Chaicharn Deerochanawong:1
1:Rajavithi hospital, College of Medicine, Rangsit University, Thailand

Pulmonary hypertension

[Speaker] Wook-Jin Chung:1
1:Gachon University Gil Medical Center, Korea

Arrhythmia

[Speaker] Yasuo Okumura:1
1:Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo

Keynote Lecture
Target of Management of ACHD in (Australia and) New Zealand

[Speaker] O'Donnell Clare P.:1
1:Green Lane Paediatric and Congenital Cardiology, New Zealand

Reconsideration of Reoperative Indication in the Long Time Period after Repair of Tetralogy of Fallot

[Speaker] Takayoshi Ueno:1
[Co-author] Tomomitsu Kanaya:1, Naoki Okuda:1, Takuji Watanabe:1, Yuji Tominaga:1, Koichi Toda:1, Toru Kuratani:1, Yoshiki Sawa:1
1:Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita

Role of Heart Team and Blood Flow Imaging in Reoperation in Adult Congenital Heart Disease

[Speaker] Keiichi Itatani:1
[Co-author] Masaaki Yamagishi:2, Yoshinobu Maeda:2, Shuhei Fujita:2, Hisayuki Hongu:2, Yuji Takayanagi:2, Hiroki Nakatuji:2, Masao Takigami:3, Michiyo Yamano:3, Naohiko Nakanishi:3, Yo Kajiyama:4, Hiroko Morichi:1, Satoaki Matoba:3, Hitoshi Yaku:1
1:Department of Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, 2:Department of Pediatric Cardiovascular Surgery, Kyoto Prefectural University of Medicine, Kyoto, 3:Department of Cardiology, Kyoto Prefectural University of Medicine, Kyoto, 4:Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto

The Impact of Onset Age of Protein Losing Enteropathy on Clinical Outcomes in Adults with and without Fontan Circulation

[Speaker] Norihisa Toh:1
[Co-author] Yasuhiro Kotoni:2, Teiji Akagi:1, Fumi Yokohama:1, Yosuke Kuroko:2, Kenji Baba:3, Shin-Ichi Otsuki:3, Shingo Kasahara:2, Hiroshi Itoh:1
1:Department of Cardiology, Okayama University, Okayama, 2:Department of Cardiovascular Surgery, Okayama University, Okayama, 3:Department of Pediatric Cardiology, Okayama University, Okayama

Surgical Approach for Failing Fontan in Adult

[Speaker] Hideki Tatewaki:1
[Co-author] Ichiro Sakamoto:2, Ayako Ishikita:2, Hazumu Nagata:3, Kenichiro Yamamura:3, Hiroyuki Tsutsui:2, Akira Shiose:1
1:Department of Cardiovascular Surgery, Kyushu University, Fukuoka, 2:Department of Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, 3:Department of Pediatrics, Kyushu University Hospital, Fukuoka

Discussion

Introduction

[Speaker] Kazuhiro Yamamoto:1
1:Division of Cardiovascular Medicine, Endocrinology and Metabolism, Faculty of Medicine, Tottori University, Tottori

Cancer associated heart failure

[Speaker] Kazuaki Negishi:1
1:The University of Sydney, Australia

Heart failure associated with arrhythmia

[Speaker] Hsin-Yueh Liang:1
1:Division of Cardiology, Dept. of Internal Medicine, China Medical University Hospital, Taiwan

Heart failure related to pericardial disease

[Speaker] Pui Wai Alex Lee:1
1:The Chinese University of Hong Kong, Hong Kong

Heart failure requiring implantable LVAD

[Speaker] Yasushi Sakata:1
1:Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita

Plaque Imaging for Clinical Practice

[Speaker] Stephen Nicholls:1
1:MonashHeart, Monash health and Cardiology Monash University, State of Victoria, Australia

A Multicenter Prospective Observational Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (J'xactly Study)

[Speaker] Yasuo Okumura:1
1:Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo

Commentary

[Speaker] Satoaki Matoba:1
1:Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto

Discussion

Syncope and R-J Interval in V1 Lead are Independent Predictors of Ventricular Fibrillation in Brugada Syndrome

[Speaker] Naoya Hironobe:1
1:Department of Cardiovascular Medicine, Hiroshima University, Hiroshima

Commentary

[Speaker] Takeru Makiyama:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Discussion

One-Year-Outcomes Post Cryoballoon Ablation for Atrial Fibrillation in Japan: Final Safety and Efficacy Results from the Cryo AF Global Registry

[Speaker] Masaomi Kimura:1
1:Advanced Management of Cardiac Arrhythmias, Hirosaki University Graduate School of Medicine, Hirosaki

Commentary

[Speaker] Koji Fukuzawa:1
1:Section of Arrhythmia, Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe

Discussion

Over 3-year time Trends of Anticoagulant Use and Outcomes in Patients with Non-valvular Atrial Fibrillation: Findings from the RAFFINE Registry

[Speaker] Sakiko Miyazaki:1
1:Department of Cardiology, Juntendo University School of Medicine, Tokyo

Commentary

[Speaker] Yukihiro Koretsune:1
1:National Hospital Organization, Osaka National Hospital, Osaka

Discussion

Coronary CT Angiography Will Replace Invasive Angiography: A 360 Degree View Point

[Speaker] Patrick W. Serruys:1
1:National University of Ireland Galway, Ireland

State-of-the-Art
Diagnosis and management of patients with non-atherosclerotic aneurysms

[Speaker] Florian Schoenhoff:1
1:University Hospital Bern, Switzerland

Open Repair for Dissecting Thoracoabdominal Aortic Aneurysm in Patients with Marfan Syndrome

[Speaker] Kyokun Uehara:1
[Co-author] Hitoshi Matsuda:1, Takanori Kaneko:1, Jiro Matsuo:1, Yosuke Inoue:1, Takayuki Shijo:1, Yoshimasa Seike:1, Hiroaki Sasaki:1, Junjiro Kobayashi:1
1:Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita

One-stage Repair for Dissecting Aneurysm from the Aortic Arch down to the Descending or Thoracoabdominal Aorta

[Speaker] Atsushi Omura:1
[Co-author] Katsuhiro Yamanaka:1, Hidekazu Nakai:1, Soichiro Henmi:1, Takeshi Inoue:1, Hitoshi Matsuda:2, Yutaka Okita:3, Kenji Okada:1
1:Department of Cardiovascular Surgery, Kobe University School of Medicine, Kobe, 2:National Cerebral and Cardiovascular Center, Suita, 3:Takatsuki General Hospital, Takatsuki

Surgical Strategies for Non-Atherosclerotic Aortic Diseases

[Speaker] Hitoshi Ogino:1
[Co-author] Toshiya Nishibe:1, Shoji Fukuda:1, Kentaro Kamiya:1, Tohru Iwahashi:1, Satoshi Takahashi:1, Shoya Iwahori:1, Keita Maruno:1, Masaki Kano:1, Ryumon Matsumoto:1, Yu Nakano:1
1:Department of Cardiovascular Surgery, Tokyo Medical University, Tokyo

High Incidence of Reoperation after Repairment of Ascending Aorta and Aortic Valve in Patients with Takayasu Arteritis

[Speaker] Ryohei Takeishi:1
[Co-author] Mitsuaki Isobe:1, Mahoto Kato:1, Mamoru Nanasato:1, Tomoki Shimokawa:2, Nobuo Iguchi:1, Shuichiro Takanashi:2
1:Department of Cardiology, Sakakibara Heart Institute, Tokyo, 2:Department of Cardiovascular Surgery, Sakakibara Heart Institute, Tokyo

Long-term Results of Hybrid/Endovascular Repair in Patients with Marfan Syndrome

[Speaker] Kazuo Shimamura:1
[Co-author] Toru Kuratani:1, Keiwa Kin:2, Kenta Masada:2, Toru Ide:2, Takasumi Goto:2, Takayoshi Ueno:2, Koichi Toda:2, Yoshiki Sawa:2
1:Department of Minimally Invasive Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, 2:Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita

State-of-the-Art
Current and Future Treatments in ATTR Amyloidosis

[Speaker] Pablo Garcia-Pavia:1
1:Hospital Universitario Puerta de Hierro, Spain

The Utility of “Kumamoto Criteria” for Selection of Elderly Patients Suspected Transthyretin Cardiac Amyloidosis

[Speaker] Seiji Takashio:1
[Co-author] Kyohhei Marume:1, Masato Nishi:1, Mami Morioka:1, Kenji Sakamoto:1, Eiichiro Yamamoto:1, Koichi Kaikita:1, Kenichi Tsujita:1
1:Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto

Utility of ^99mTc-Pyrophosphate Scintigraphy in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practice

[Speaker] Toru Kubota:1
1:Division of Cardiology, Cardiovascular and Aortic Center, Saiseikai Fukuoka General Hospital, Fukuoka

Natural History and Echocardiographic Disease Progression of Japanese Transthyretin Amyloid Cardiomyopathy

[Speaker] Atsushi Okada:1
[Co-author] Yasuhiro Shintani:1, Kenji Moriuchi:1, Yasuhiro Hamatani:1, Masashi Amano:1, Hiroyuki Takahama:1, Makoto Amaki:1, Takuya Hasegawa:1, Hideaki Kanzaki:1, Hatsue Ishibashi-Ueda:2, Satoshi Yasuda:1, Chisato Izumi:1
1:Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, 2:National Cerebral and Cardiovascular Center, Suita

Arrhythmia is Common but Important Clue to Detect Hidden Wild-type Transthyretin Cardiac Amyloidosis -The Possibility of Two Original Methods-

[Speaker] Keiji Matsunaga:1
[Co-author] Takahisa Noma:1, Genki Kurashita:1, Takuma Sakamoto:1, Takahiro Izumi:1, Tomoko Inoue:1, Eriko Nasu:1, Shohei Miyai:1, Atsushi Tobiume:1, Shota Yokoyama:1, Hideyuki Hamaya:1, Shohei Ishikawa:1, Takayuki Honjo:1, Ryo Kawakami:1, Yuichi Miyake:1, Makoto Ishizawa:1, Kaori Ishikawa:1, Kazushi Murakami:1, Tetsuo Minamino:1
1:Department of Cardiorenal and Cerebrovascular Medicine, School of Medicine, Kagawa University, Kagawa

CURRENT AS Registry-2; Study Design and Objectives

[Speaker] Yasuaki Takeji:1
1:Kyoto University Graduate School of Medicine, Kyoto

Changes in Patient Characteristics and Treatment Strategy for Severe AS from the CURRENT AS Registry-1 and -2

[Speaker] Ryosuke Murai:1
1:Department of Cardiology, Kurashiki Central Hospital, Kurashiki

Multi-view Approach in Echocardiography for Severe AS from the CURRENT AS Registry-2

[Speaker] Makoto Miyake:1
1:Department of Cardiology, Tenri Hospital, Tenri

Asymptomatic Severe AS; Decision Making for Intervention Using 6 Minutes Walk and Exercise Test from the CURRENT AS Registry-2

[Speaker] Tomohiko Taniguchi:1
1:Department of Cardiology, Kokura Memorial Hospital, Kitakyushu

Procedural Characteristics and In-hospital Outcomes in Patients Undergoing SAVR or TAVI from the CURRENT AS Registry-1 and -2

[Speaker] Tomohisa Tada:1
1:Cardiovascular Medicine, Shizuoka General Hospital, Shizuoka

Case Presentation

[Speaker] Moritoshi Funasako:1
1:Na Homolce Hospital, Czech Republic

Mechanism of Downward Spiral in Patients with Atrial Fibrillation and Heart Failure

[Speaker] Takao Kato:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Therapeutic Options for Heart Failure with Atrial Fibrillation; Evidence from Past Studies

[Speaker] Kazuhiro Satomi:1
1:Tokyo Medical University, Tokyo

What is the Risk Factors for Developing Heart Failure in AF Patients ? Insights from Fushimi AF Registry

[Speaker] Yoshimori An:1
1:National Hospital Organization Kyoto Medical Center, Department of Cardiology, Kyoto

How to Manage Refractory HF with AF?: From EP Specialist

[Speaker] Kazuaki Kaitani:1
1:Department of Cardiology, Otsu Red Cross Hospital, Otsu

How to Manage Refractory HF with AF?: From HF Specialists

[Speaker] Yasushi Sakata:1
1:Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita

Closing Remarks

[Speaker] Andreas Goette:1
1:St. Vincenz Hospital Paderborn, Germany

Keynote Lecture
Progress in CTEPH Treatment

[Speaker] Hiromi Matsubara:1
1:National Hospital Organization Okayama Medical Center, Okayama

The Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with CTEPH

[Speaker] Kazuya Hosokawa:1
[Co-author] Kohtaro Abe:1, Kota Funakoshi:2, Koji Todaka:2, Hiroyuki Tsutsui:1
1:Department of Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, 2:Center for Clinical and Translational Research, Fukuoka

Multi-step Therapy with Riociguat, Balloon Pulmonary Angioplasty, and Cardiac Rehabilitation for Chronic Thromboembolic Pulmonary Hypertension

[Speaker] Shigefumi Fukui:1
[Co-author] Koichiro Sugimura:1, Shunsuke Tatebe:1, Ryo Konno:1, Yosuke Terui:1, Haruka Sato:1, Saori Yamamoto:1, Tatsuo Aoki:2, Kimio Satoh:1, Takeshi Ohgoh:2, Hiroaki Shimokawa:1
1:Department of Cardiovascular Medicine, Tohoku University Hospital, Sendai, 2:Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita

The Role of Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension, Current and Future Direction

[Speaker] Yu Taniguchi:1
[Co-author] Yoichiro Matsuoka:1, Hiroyuki Onishi:1, Noriaki Emoto:1, Hidekazu Nakai:2, Kenji Okada:2, Kenichi Hirata:1
1:Department of Cardiovascular Medicine, Kobe University Graduate School of Medicine, Kobe, 2:Department of Cardiovascular Surgery, Kobe University Graduate School of Medicine, Kobe

Pulmonary Endarterectomy with Pavia Technique

[Speaker] Keiichi Ishida:1
1:Department of General Science Medicine, Chiba University Graduate School of Medicine, Chiba

Trends in Management and Long-term Outcome in Coronary Revascularization over Recent Decades in Japan: Insight from the CREDO-Kyoto Registry Cohort-1, 2, and 3

[Speaker] Hiroki Shiomi:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Clinical Outcomes after PCI Using 1st and 2nd Generation DES: Insight from the CREDO-Kyoto Registry Cohort-2 and -3

[Speaker] Yusuke Yoshikawa:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Comparison of Clinical Outcomes after PCI and CABG in Patients with Triple Vessel Disease from the CREDO-Kyoto Registry Cohort-3

[Speaker] Yukiko Nakano:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Comparison of Clinical Outcomes after PCI and CABG in Patients with Left Main Coronary Artery Disease from the CREDO-Kyoto Registry Cohort-3

[Speaker] Ko Yamamoto:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Incidence and Clinical Outcomes of CAD Patients with Concomitant Cancer in the CREDO-Kyoto Registry Cohort-3

[Speaker] Kazuaki Imada:1
1:Department of Cardiology, Kokura Memorial Hospital, Kitakyushu

Trends in Practice Pattern and Clinical Outcomes in Acute Myocardial Infarction from the CREDO-Kyoto AMI Registry Wave-1 (2005-2007) to Wave-2 (2011-2013)

[Speaker] Yasuaki Takeji:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Keynote Lecture
Selective Use of Coronary Revascularization would be Appropriate Even in Patients with Documented Myocardial Ischemia after ISCHEMIA Trial

[Speaker] John A. Spertus:1
1:Saint Luke's Mid America Heart Institute/UMKC, USA

Keynote Lecture
Coronary Revascularization would be Appropriate in Most Patients with “Truly” Documented Myocardial Ischemia even after ISCHEMIA Trial

[Speaker] Stephan Windecker:1
1:Bern University Hospital, Switzerland

Discussion

Responses of Japanese Patients to the Participation in the ISCHEMIA Trial, and How We should Inform Them with the Results

[Speaker] Shun Kohsaka:1
[Co-author] Toshiyuki Nagai:2, Shintaro Nakano:3
1:Department of Cardiology, Keio University School of Medicine, Tokyo, 2:Department of Cardiovascular Medicine, Hokkaido University, Sapporo, 3:Department of Cardiology, Saitama Medical University, International Medical Center, Saitama

Assessment of Coronary Physiology in Stable Coronary Syndrome -The Evidence and Implications from Pressure Wire Based Physiological Assessment

[Speaker] Hitoshi Matsuo:1
1:Department of Cardiovascular Medicine, Gifu Heart Center, Gifu

How We Apply the ISCHEMIA Trial Results into Daily Clinical Practice

[Speaker] Adnan Kastrati:1
1:Deutsches Herzzentrum München, Germany

Final Thought on Coronary Revascularization in Patients with Chronic Coronary Syndrome

[Speaker] Patrick W. Serruys:1
1:National University of Ireland Galway, Ireland

High-intensity Statins Therapy should also be Recommended in Elderly CAD Patients

Pros: High-intency Statins Work Regardless of Age

[Speaker] Takahiro Horie:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Cons: Strict Target is not Necessary for the Elderly

[Speaker] Shin-Ichiro Miura:1
1:Department of Cardiology, Fukuoka University School of Medicine, Fukuoka

Discussion

Selective PPARα Modulator is the Next Choice for Patients Already Treated with Statin

Pros: Therapeutic Potential of SPPARMα Modulator in Combination with Statin

[Speaker] Jean-Charles B. Fruchart:1
1:R3i Foundation, Morocco

Pros: PCSK9 Inhibitors Substantially Lower Atherogenic Lipoproteins and Reduce CV Risk

[Speaker] Marc S. Sabatine:1
1:TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, USA

Discussion

Should We Increase HDL?

Pros: HDL is Associated with Cardiovascular Disease

[Speaker] Shinji Yokoyama:1
1:Chubu University, Institute for Biological Functions, Kasugai

Cons: Not Quantity but Quality Matters

[Speaker] Stephen J. Nicholls:1
1:Monash Heart, Monash University, Australia

Discussion

High Dose Eicosapentaenoic Acid Ethyl Ester to Treat Residual Cardiovascular Risk

Pros: High Dose for Maximum Benefit

[Speaker] Deepak Bhatt:1
1:Brigham and Women's Hospital, Harvard Medical School, USA

Cons: Low Dose is Enough for Japanese Patients

[Speaker] Hiroyuki Daida:1
1:Faculty of Health Science, Juntendo University, Tokyo

Discussion

State-of-the-Art
Hypertension 2020 -Towards a Global Consensus in Clinical Practice Guidelines

[Speaker] Bryan Williams:1
1:University College London, UK

Staging Cardiac Damage in Patients with Hypertension

[Speaker] Yuta Seko:1
[Co-author] Takao Katoh:1, Moriaki Inoko:2, Takeshi Kimura:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 2:Cardiovascular Center, Kitano Hospital, The Tazuke Kofukai, Medical Research Institute, Osaka

Presence or Severity of Coronary Artery Disease in Patients with Intensive Lowering Blood Pressure at Coronary Computed Tomography Angiography

[Speaker] Yasunori Suematsu:1
[Co-author] Yuhei Shiga:1, Yohei Tsukihashi:1, Shinichiro Miura:1
1:Department of Cardiology, Fukuoka University, Fukuoka

Association between Central Blood Pressure and Subclinical Cerebrovascular Disease in Older Adults: A Community-Based Cohort Study

[Speaker] Kenji Matsumoto:1
[Co-author] Shunichi Homma:1, Marco Di Tullio:1
1:Department of Medicine, Columbia University, USA

Rationales of Strict Blood Pressure Control in Patients with Cardiovascular Disease

[Speaker] Hisashi Kai:1
1:Department of Cardiology, Kurume University Medical Center, Kurume

Smoking as an important factor of the disease progression in COVID-19

[Speaker] Koji Hasegawa:1
1:Member, World Heart Federation Tobacco Expert Group (WHF-TEG) / National Hospital Organization Kyoto Medical Center, Kyoto

Ending Tobacco in Asia

[Speaker] Edgardo Ulysses DOROTHEO:1
1:Executive Director, Southeast Asia Tobacco Control Alliance (SEATCA), Philippines

Regional Action Plan for Tobacco Control in the Western Pacifific (2020–2030)

[Speaker] Ada Moadsiri:1
1:Technical Officer, Noncommunicable diseases, WHO-WPRO, Division of Pacific Technical Support, Fiji

Section 1 Implement High-intensity Statins Therapy in Most Japanese Patients with Coronary Artery Disease

Section 1. Opening Lecture

[Speaker] Katsumi Miyauchi:1
1:Juntendo Tokyo Geriatric Medical Center, Tokyo

Section 1. Audience Response

Section 1. Position Statement

[Speaker] Takeshi Kimura:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusions

[Speaker] Hiroyuki Daida:1
1:Faculty of Health Science, Juntendo University, Tokyo

Section 2 Aspirin is not Indicated in Most Patients for Primary Prevention

Section 2. Opening Lecture

[Speaker] Sadanori Okada:1
1:Center for Postgraduate Training, Department of Diabetes and Endocrinology, Nara Medical University, Nara

Section 2. Audience Response

Section 2. Position Statement

[Speaker] Deepak Bhatt:1
1:Brigham and Women's Hospital, Harvard Medical School, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusions

[Speaker] Nobuhisa Hagiwara:1
1:Department of Cardiology, Tokyo Women's Medical University, Tokyo

Section 3 Management of Diabetes should be Drastically Changed from Pharmacologic Glucosecentric Approach to Intensive Life Style Changes Focusing on Patients-centric Outcomes:

Section 3. Opening Lecture

[Speaker] Neiko Ozasa:1
1:Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto

Section 3. Audience Response

Section 3. Position Statement

[Speaker] Rodriguez-Gutierrez Rene:1
1:Universidad Autonoma de Nuevo Leon, Mayo Clinic, Mexico

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusions

[Speaker] Hiroshi Ito:1
1:Department of Cardiovascular Medicine, Okayama University, Okayama

Section 1. Adverse Effects of Antiarrhythmic Drugs are still Underrecognized and Underestimated: An Old and New Issue to be Solved

Section 1. Opening Lecture

[Speaker] Tetsuo Sasano:1
1:Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo

Section 1. Audience Response

Section 1. Position Statement

[Speaker] Takeshi Yamashita:1
1:The Cardiovascular Institute, Tokyo

Section 1. Discussion

Section 1. Audience Response

Section 1. Conclusion

[Speaker] Tetsuo Sasano:1
1:Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo

Section 2. Catheter Ablation is Reasonable as First-line Therapy for Highly Symptomatic AF

Section 2. Opening Lecture

[Speaker] David Spragg:1
1:Johns Hopkins University School of Medicine, USA

Section 2. Audience Response

Section 2. Position Statement

[Speaker] Douglas L. Packer:1
1:Mayo Clinic Hospital, USA

Section 2. Discussion

Section 2. Audience Response

Section 2. Conclusion

[Speaker] David Spragg:1
1:Johns Hopkins University School of Medicine, USA

Section 3. Catheter Ablation is an Important Option for AF Patients with Heart Failure and/or Reduced LVEF

Section 3. Opening Lecture

[Speaker] Akihiko Nogami:1
1:Department of Cardiology, University of Tsukuba, Tsukuba

Section 3. Audience Response

Section 3. Position Statement

[Speaker] Nassir F. Marrouche:1
1:Tulane University Heart & Vascular Institute, USA

Section 3. Discussion

Section 3. Audience Response

Section 3. Conclusion

[Speaker] Akihiko Nogami:1
1:Department of Cardiology, University of Tsukuba, Tsukuba

1. Optimal Revascularization and Percutaneous Support Device from STEMI with Cardiogenic Shock

1. Keynote Lecture

[Speaker] Navin K. Kapur:1
1:Tufts Medical Center, USA

1. Audience Response

1. STEMI Case with Cardiogenic Shock

[Speaker] Shunsuke Kubo:1
1:Department of Cardiology, Kurashiki Central Hospital, Kurashiki

1. Audience Response・Discussion

1. How to Use IMPELLA Most Effectively for Cardiogenic Shock Patients ?

[Speaker] Jun Nakata:1
1:Division of Cardiovascular Intensive Care, Nippon Medical School Hospital, Tokyo

1. What is the Role of IABP in Current Mechanical Support Era ?

[Speaker] Taku Inohara:1
1:Division of Cardiology, Vancouver General Hospital, Canada

2. Optimal Management of Profound Cardiogenic Shock Patients (Post Cardiac Arrest)

2. Fulminant Myocarditis

[Speaker] Koichi Toda:1
1:Department of Cardiovascular Surgery, Osaka Univ. Graduate School of Medicine, Suita

2. Audience Response・Discussion

2. How can We Detect and Treat Right Ventricular Failure in Profound Shock Patients ?

[Speaker] Koichiro Kinugawa:1
1:The Second Department of Internal Medicine, University of Toyama, Toyama

2. How to Plan the Limb Salvage Strategy in MCS Patients?

[Speaker] Navin K. Kapur:1
1:Tufts Medical Center, USA

2. What is the Timing to Upgrade Percutaneous Support Device to Surgical Device ?

[Speaker] Masashi Kawabori:1
1:Tufts Medical Center, Tufts University School of Medicine, USA